Boston-based healthcare-focused VC firm Vida Ventures has raised $254.8 million for a new fund, according to a Boston Business Journal report.
The executive roster for the fund includes former Kite Pharmaceuticals CEO Arie Belldegrun and San Francisco-based private equity firm TPG’s former partner Fred Cohen, according to the report. Other execs on the fund include Leonard Potter and former principals at Third Rock Ventures and 5AM Ventures, both based in Boston.
A total of 58 individuals contributed to the fund, according to an SEC filing, with the first sale noted on November 29, 2017.
The VC firm has not yet revealed direct plans for the fund, but in August the VC firm invested in Bedford, Mass.-based Homology Medicines, which looks to be developing gene-editing drugs, according to the Boston Business Journal report. Last week, the company was also noted on a list of investors for San Francisco-based Pionyr Immunotherapeutics.
Last week, European life sciences investment group LSP said it closed its new $330 million (EU €280 million) medical technology fund.